Master data| INID | Criterion | Field | Content |
|---|
| Type of IP right | SART | Patent |
| Status | ST | Not pending/lapsed |
| 21 | DE file number | DAKZ | 602 48 937.7 |
| 96 | EP file number | EAKZ | 14 16 4259.5 |
| 97 | EP publication number | EPN | 2783686 |
| 54 | Designation/title | TI | Kombination aus einem Rapamycin Derivat und Letrozol zur Behandlung von Brustkrebs |
| 51 | IPC main class | ICM
(ICMV) | A61K 31/4196 (2006.01) |
| 51 | IPC secondary class(es) | ICS
(ICSV) | A61K 31/436 (2006.01), A61P 35/00 (2006.01), A61K 31/337 (2006.01), A61K 31/502 (2006.01), A61K 31/704 (2006.01), A61K 31/7068 (2006.01), A61K 33/24 (2019.01) |
| 22 | DE application date | DAT | Feb 18, 2002 |
| 96 | EP application date | EAT | Feb 18, 2002 |
| 43 | Date of first publication | OT | Oct 1, 2014 |
| Date of publication of grant | PET | Jun 21, 2017 |
| 71/73 | Applicant/owner | INH | Novartis International Pharmaceutical AG, Basel, CH; Novartis Pharma AG, Basel, CH |
| 72 | Inventor | IN | Lane, Heidi, 4106 Therwill, CH; O'Reilly, Terence, 4057 Basel, CH; Wood, Jeanette Marjorie, 4105 Biel-Benken, CH |
| Address for service | | Novartis Pharma AG, 4056 BASEL, CH |
33
31
32
| Foreign priority | PRC
PRNA
PRDA
| GB
0104072
Feb 19, 2001
|
33
31
32
| Foreign priority | PRC
PRNA
PRDA
| GB
0124957
Oct 17, 2001
|
| Patent division in charge | | 44 |
| 97 | EP language of publication | ELANG | EN - Englisch |
| 84 | Designated EP contracting states | EDS | AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE, TR |
| Published EP/WO documents | EPWOPN | Original document:
EP000002783686
Searchable text:
EP000002783686
Original document:
EP000002783686B1
Searchable text:
EP000002783686B1 |
| 43 | Date of first publication | EVT | Oct 1, 2014 |
| Date of the first transfer into DPMAregister | EREGT | Nov 14, 2014 |
| Date of the (most recent) update in DPMAregister | REGT | Jan 7, 2024
(Show all update days)(Hide all update days)- Nov 14, 2014
- Date of the first transfer into DPMAregister
|
